A PLGA-encapsulated chimeric protein protects against adherence and toxicity of enterotoxigenic Escherichia coli

Microbiological Research

Volumn 169, Issue 2-3, 2014, Pages 205-212

  Nazarian, Shahram ^a   Gargari, Seyed Latif Mousavi ^a   Rasooli, Iraj ^a   Hasannia, Sadegh ^b   Pirooznia, Nazanin ^c  

^a SHAHED UNIVERSITY   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c UNIVERSITY OF GUILAN   (Iran)

Author keywords

Biodegradable PLGA; Enterotoxigenic E. coli; Nanoparticles; Oral immunization

Indexed keywords

AVERAGE PARTICLE SIZE; BIODEGRADABLE PLGA; E. COLI; ENCAPSULATION EFFICIENCY; ENTEROTOXIGENIC ESCHERICHIA COLI; FLUID ACCUMULATION; MUCOSAL IMMUNE RESPONSE; POLY(LACTIC-CO-GLYCOLIC ACID);

ANTIBODIES; EMULSIFICATION; ENCAPSULATION; ESCHERICHIA COLI; IMMUNIZATION; MAMMALS; NANOPARTICLES; VACCINES;

COPOLYMERS;

ANTIBODY; COLONIZATION; DIARRHEAL DISEASE; DRUG DEVELOPMENT; IMMUNE RESPONSE; MICROBIAL ACTIVITY; PROTEIN;

ESCHERICHIA COLI; MUS;

BACTERIUM ANTIBODY; ENTEROTOXIN; ESCHERICHIA COLI PROTEIN; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL; ARTICLE; BACTERIUM ADHERENCE; BAGG ALBINO MOUSE; BIODEGRADABLE PLGA; CACO 2 CELL LINE; CHEMISTRY; ENTEROTOXIGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HUMAN; IMMUNIZATION; IMMUNOLOGY; MICROBIOLOGY; MOUSE; PHYSIOLOGY;

BIODEGRADABLE PLGA; ENTEROTOXIGENIC E. COLI; NANOPARTICLES; ORAL IMMUNIZATION;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL ADHESION; CACO-2 CELLS; ENTEROTOXIGENIC ESCHERICHIA COLI; ENTEROTOXINS; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FEMALE; HUMANS; LACTIC ACID; MICE; MICE, INBRED BALB C; POLYGLYCOLIC ACID;

EID: 84891625768     PISSN: 09445013     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.micres.2013.06.005     Document Type: Article

References (39)

1. Alves A.M., Lásaro M.O., Almeida D.F., Ferreira L.C. Immunoglobulin G subclass responses in mice immunized with plasmid DNA encoding the CFA/I fimbria of enterotoxigenic Escherichia coli. Immunol Lett 1998, 62:145-149.
2. Amani J., Salmanian A.H., Rafati S., Mousavi S.L. Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157:H7. Vaccine 2010, 28:6923-6929.
3. Arai R., Ueda H., Kitayama A., Kamiya N., Nagamune T. Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng 2001, 14:529-532.
4. Borges O., Tavares J., de S.A., Borchard G., Junginger H.E., Cordeiro-da-Silva A. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur J Pharm Sci 2007, 32:278-290.
5. Byrd W., Cassels F.J. Mucosal immunization of BALB/c mice using enterotoxigenic Escherichia coli colonization factors CFA/I and CS6 administered with and without a mutant heat-labile enterotoxin. Vaccine 2003, 21:1884-1893.
6. Byrd W., Cassels F.J. The encapsulation of enterotoxigenic Escherichia coli colonization factor CS3 in biodegradable microspheres enhances the murine antibody response following intranasal administration. Microbiology 2006, 152:779-786.
7. Byrd W., de L.A., Zheng Z.R., Cassels F.J. Microencapsulated subunit vaccine approach to enterotoxigenic Escherichia coli and other mucosal pathogens. Adv Drug Deliv Rev 2005, 57:1362-1380.
8. Chen X., Zaro J.L., Shen W.C. Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev 2012, 12:10.
9. Coombes A.G.A., Yeh M.K., Lavelle E.C., Davis S.S. The control of protein release from poly(dl-lactide co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. J Control Release 1998, 52:311-320.
10. Danhier F., Ansorena E., Silva J.M., Coco R., Le B.A., Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012, 161:505-522.
11. de Lorimier A.J., Byrd W., Hall E.R., Vaughan W.M., Tang D., Roberts Z.J., et al. Murine antibody response to intranasally administered enterotoxigenic Escherichia coli colonization factor CS6. Vaccine 2003, 21:2548-2555.
12. De S.N., Chatterje D.N. An experimental study of the mechanism of action of Vibrio cholerae on the intestinal mucous membrane. J Pathol Bacteriol 1953, 66:559-562.
13. Eldridge J.H., Staas J.K., Meulbroek J.A., McGhee J.R., Tice T.R., Gilley R.M. Biodegradable microspheres as a vaccine delivery system. Mol Immunol 1991, 28:287-294.
14. Fingerut E., Gutter B., Meir R., Eliahoo D., Pitcovski J. Vaccine and adjuvant activity of recombinant subunit B of E. coli enterotoxin produced in yeast. Vaccine 2005, 23:4685-4696.
15. Garinot M., Fievez V., Pourcelle V., Stoffelbach F., des R.A., Plapied L., et al. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release 2007, 120:195-204.
16. Gupta S.K., Keck J., Ram P.K., Crump J.A., Miller M.A., Mintz E.D. Part III. Analysis of data gaps pertaining to enterotoxigenic Escherichia coli infections in low and medium human development index countries, 1984-2005. Epidemiol Infect 2008, 136:721-738.
17. Isidean S.D., Riddle M.S., Savarino S.J., Porter C.K. A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression. Vaccine 2011, 29:6167-6178.
18. Kim T.G., Kim B.G., Kim M.Y., Choi J.K., Jung E.S., Yang M.S. Expression and immunogenicity of enterotoxigenic Escherichia coli heat-labile toxin B subunit in transgenic rice callus. Mol Biotechnol 2010, 44:14-21.
19. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B: Biointerfaces 2010, 75:1-18.
20. McGee J.P., Davis S.S., O'Hagan D.T. The immunogenicity of a model protein entrapped in poly(lactide-co-glycolide) microparticles prepared by a novel phase separation technique. J Control Release 1994, 31:55-60.
21. Nazarian S., Mousavi Gargari S.L., Rasooli I., Amani J., Bagheri S., Alerasool M. An in silico chimeric multi subunit vaccine targeting virulence factors of enterotoxigenic Escherichia coli (ETEC) with its bacterial inbuilt adjuvant. J Microbiol Methods 2012, 90:36-45.
22. Park J., Mattessich T., Jay S.M., Agawu A., Saltzman W.M., Fahmy T.M. Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates. J Control Release 2011, 156:109-115.
23. Pavot V., Rochereau N., Genin C., Verrier B., Paul S. New insights in mucosal vaccine development. Vaccine 2012, 30:142-154.
24. Petri W.A., Miller M., Binder H.J., Levine M.M., Dillingham R., Guerrant R.L. Enteric infections, diarrhea, and their impact on function and development. J Clin Invest 2008, 118:1277-1290.
25. Qadri F., Ryan E.T., Faruque A.S., Ahmed F., Khan A.I., Islam M.M., et al. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers. Infect Immun 2003, 71:4808-4814.
26. Qadri F., Wenneras C., Ahmed F., Asaduzzaman M., Saha D., Albert M.J., et al. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children. Vaccine 2000, 18:2704-2712.
27. Qadri F., Svennerholm A.M., Faruque A.S.G., Sack R.B. Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin Microbiol Rev 2005, 18:465-483.
28. Sabui S., Ghosal A., Dutta S., Ghosh A., Ramamurthy T., Nataro J.P., et al. Allelic variation in colonization factor CS6 of enterotoxigenic Escherichia coli isolated from patients with acute diarrhoea and controls. J Med Microbiol 2010, 59:770-779.
29. Sanchez J., Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin Immunol 2005, 17:388-398.
30. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997, 28:5-24.
31. Subekti D.S., Lesmana M., Tjaniadi P., Machpud N., Sriwati, Sukarma, et al. Prevalence of enterotoxigenic Escherichia coli (ETEC) in hospitalized acute diarrhea patients in Denpasar, Bali, Indonesia. Diagn Microbiol Infect Dis 2003, 47:399-405.
32. Svennerholm A.M., Lundgren A. Recent progress toward an enterotoxigenic Escherichia coli vaccine. Expert Rev Vaccines 2012, 11:495-507.
33. Svennerholm A.M., Tobias J. Vaccines against enterotoxigenic Escherichia coli. Expert Rev Vaccines 2008, 7:795-804.
34. Takahashi I., Nochi T., Yuki Y., Kiyono H. New horizon of mucosal immunity and vaccines. Curr Opin Immunol 2009, 21:352-358.
35. Tobias J., Svennerholm A.M., Carlin N.I., Lebens M., Holmgren J. Construction of a non-toxigenic Escherichia coli oral vaccine strain expressing large amounts of CS6 and inducing strong intestinal and serum anti-CS6 antibody responses in mice. Vaccine 2011, 29:8863-8869.
36. Tobias J., Vutukuru S.R. Simple and rapid multiplex PCR for identification of the main human diarrheagenic Escherichia coli. Microbiol Res 2012, 167:564-570.
37. Vert M., Mauduit J., Li S. Biodegradation of PLA/GA polymers: increasing complexity. Biomaterials 1994, 15:1209-1213.
38. Verweij W.R., de H.L., Holtrop M., Agsteribbe E., Brands R., van Scharrenburg G.J., et al. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine 1998, 16:2069-2076.
39. Wagner B., Hufnagl K., Radauer C., Wagner S., Baier K., Scheiner O., et al. Expression of the B subunit of the heat-labile enterotoxin of Escherichia coli in tobacco mosaic virus-infected Nicotiana benthamiana plants and its characterization as mucosal immunogen and adjuvant. J Immunol Methods 2004, 287:203-215.